Durvalumab plus tremelimumab in unresectable hepatocellular carcinoma.

ABSTRACT:

SUBMITTER: Kudo M 

PROVIDER: S-EPMC9396100 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature